Sakar Healthcare Limited Asset Resilience Ratio
Sakar Healthcare Limited asset resilience ratio. Sakar Healthcare Limited (SAKAR) has an Asset Resilience Ratio of 0.05% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Sakar Healthcare Limited (SAKAR) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Sakar Healthcare Limited (2017–2026)
Asset resilience ratio of Sakar Healthcare Limited from 2017 to 2026. This chart shows how Sakar Healthcare Limited's Asset Resilience Ratio has changed over time. Read total liabilities of Sakar Healthcare Limited for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Sakar Healthcare Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see SAKAR total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs2.17 Million | 0.05% |
| Total Liquid Assets | Rs2.17 Million | 0.05% |
Asset Resilience Insights
- Limited Liquidity: Sakar Healthcare Limited maintains only 0.05% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Sakar Healthcare Limited Industry Peers by Asset Resilience Ratio
Compare Sakar Healthcare Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Sakar Healthcare Limited Asset Resilience Ratio by Year (2017–2026)
Sakar Healthcare Limited asset resilience ratio by year from 2017 to 2026. The table below shows the annual Asset Resilience Ratio data for Sakar Healthcare Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2026-03-31 | 0.05% | Rs2.17 Million ≈ $23.52K |
Rs4.81 Billion ≈ $52.02 Million |
-0.03pp |
| 2025-03-31 | 0.07% | Rs3.09 Million ≈ $33.45K |
Rs4.15 Billion ≈ $44.91 Million |
+0.02pp |
| 2024-03-31 | 0.05% | Rs2.08 Million ≈ $22.45K |
Rs3.89 Billion ≈ $42.03 Million |
-0.99pp |
| 2023-03-31 | 1.05% | Rs35.23 Million ≈ $380.96K |
Rs3.36 Billion ≈ $36.37 Million |
-1.61pp |
| 2022-03-31 | 2.65% | Rs71.06 Million ≈ $768.50K |
Rs2.68 Billion ≈ $28.96 Million |
-1.39pp |
| 2021-03-31 | 4.04% | Rs71.88 Million ≈ $777.41K |
Rs1.78 Billion ≈ $19.23 Million |
+3.00pp |
| 2020-03-31 | 1.04% | Rs12.01 Million ≈ $129.88K |
Rs1.15 Billion ≈ $12.45 Million |
+0.67pp |
| 2019-03-31 | 0.37% | Rs3.67 Million ≈ $39.67K |
Rs986.85 Million ≈ $10.67 Million |
-0.08pp |
| 2018-03-31 | 0.45% | Rs3.62 Million ≈ $39.18K |
Rs811.00 Million ≈ $8.77 Million |
-0.19pp |
| 2017-03-31 | 0.64% | Rs4.52 Million ≈ $48.87K |
Rs705.87 Million ≈ $7.63 Million |
-- |
About Sakar Healthcare Limited
Sakar Healthcare Limited research, develops, manufactures, and sells pharmaceutical products in India. The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrups and injections, liquid injectable (SVP) in ampoules, vials and lyophilized injections, and oral solid dosages. Its product portfolio consists of formulations in therapeutic areas, such as anti-infective, analge… Read more